The in vivo cell therapy seed Carisma Therapeutics planted with Moderna in 2022 is starting to sprout. | The in vivo cell ...

Fructose, the most common food sweetener, is widely used in processed sugary beverages, candies, and baked goods. Excessive ...

Trials with mice in whom the researchers implanted human glioblastoma cells have already shown that the treatment is very ...

Background Peritoneal metastasis is the most common metastasis pattern of gastric cancer. Patients with gastric cancer ...

Glioblastoma is the most common kind of malignant brain tumor in adults. So far, no treatment has been able to make this ...

They also wanted to study the role of Pin1 in the crosstalk between pancreatic cancer cells and the tumor microenvironment — ...

Researchers have developed an innovative CAR T-cell therapy to combat glioblastoma, the most common malignant brain tumor in ...

Corvus Pharmaceuticals Inc. (CRVS) announced new data highlighting the potential of ciforadenant, the Company's adenosine A2A ...

A team of scientists has used a novel approach to identify protein degraders that target Pin1, a protein involved in pancreatic cancer development.

This will involve moving its first cancer drug into clinical trials, and starting work on projects involving macrophages and the role they play in inflammatory diseases. Bregenholt told ...

Pheast Therapeutics (“Pheast”), a biotech developing novel macrophage checkpoint therapies to defy cancer, today announced the presentation of new preclinical data for PHST001, an anti-CD24 antibody ...

In drug discovery, targeted protein degradation is a method that selectively eliminates disease-causing proteins. A ...